These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19048001)

  • 1. Rituximab for membranous nephropathy and immune disease: less might be enough.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Clin Pract Nephrol; 2009 Feb; 5(2):76-7. PubMed ID: 19048001
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?
    Fervenza FC
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1017-9. PubMed ID: 19470660
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.
    Zhu B; Huang J
    Pediatr Nephrol; 2011 Apr; 26(4):637-8. PubMed ID: 21046167
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab in membranous nephropathy: is it a first-line treatment?
    Appel GB
    J Am Soc Nephrol; 2012 Aug; 23(8):1280-2. PubMed ID: 22797189
    [No Abstract]   [Full Text] [Related]  

  • 5. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
    Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in membranous nephropathy.
    Ring T
    Kidney Int; 2008 Aug; 74(3):391-2; author reply 392. PubMed ID: 18626501
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.
    Segarra A; Praga M; Ramos N; Polanco N; Cargol I; Gutierrez-Solis E; Gomez MR; Montoro B; Camps J
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1083-8. PubMed ID: 19478097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
    Cobo M; Hernández D; Rodriguez C; Pérez-Tamajón L
    Clin Nephrol; 2006 Jul; 66(1):54-7. PubMed ID: 16878436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment of idiopathic membranous nephropathy.
    Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
    Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy.
    Radhakrishnan RC; Basu G; George RE; Parmar H; Tamilarasi V
    Saudi J Kidney Dis Transpl; 2017; 28(3):657-660. PubMed ID: 28540910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose rituximab for recurrent glomerulonephritis post-renal transplant.
    Spinner ML; Bowman LJ; Horwedel TA; Delos Santos RB; Klein CL; Brennan DC
    Am J Nephrol; 2015; 41(1):37-47. PubMed ID: 25634230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose rituximab for posttransplant recurrent membranous nephropathy.
    Cravedi P; Ruggenenti P; Remuzzi G
    Am J Transplant; 2010 May; 10(5):1336. PubMed ID: 20199509
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
    Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
    [No Abstract]   [Full Text] [Related]  

  • 17. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
    Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy.
    Wen M; Küchle C; Sarkar O; Renders L; Heemann U; Schmaderer C
    Int Urol Nephrol; 2014 Apr; 46(4):847-8. PubMed ID: 24585365
    [No Abstract]   [Full Text] [Related]  

  • 19. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
    Maharjan R; Wang JW; Shrestha IK
    J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for idiopathic membranous nephropathy.
    Remuzzi G; Chiurchiu C; Abbate M; Brusegan V; Bontempelli M; Ruggenenti P
    Lancet; 2002 Sep; 360(9337):923-4. PubMed ID: 12354476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.